The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial.Methods In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period. Eligible patients were aged 25-75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn and Yahr stage 2·5 or less when on treatment. Randomisation was by web-based randomisation with a two strata block design according to disease severity. Patients and investigators were masked to treatment allocation. The primary outcome was the adjusted difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3) in the practically defined off-medication state at 60 weeks. All efficacy analyses were based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation follow-up assessments. The study is registered at ClinicalTrials.gov (NCT01971242) and is completed.Findings Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide and 30 to placebo. Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group. At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI -2·6 to 0·7) in the exenatide group and worsened by 2·1 points (-0·6 to 4·8) in the placebo group, an adjusted mean difference of -3·5 points (-6·7 to -0·3; p=0·0318). Injection site reactions and gastrointestinal symptoms were common adverse events in both groups. Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions.Interpretation Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials.Funding Michael J Fox Foundation for Parkinson's Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinson’s disease (15, 53).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This discrepancy may reflect differences in the neuroprotective mechanisms of semaglutide and tirzepatide vs earlier GLP-1RAs, such as exenatide, liraglutide, and lixisenatide, which have demonstrated favorable clinical benefits in early-stage Parkinson disease.33,50”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In Parkinson's disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo,53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.55”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [142]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Multiple GLP-1 medicines, including exenatide (15), liraglutide (16), semaglutide (17, 18), and tirzepatide (19), reduce plasma CRP levels in people living with T2D and/or obesity.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Moreover, GLP-1 receptors interact with various neurotransmitter systems such as serotonin, dopamine, and glutamate, which are essential for mood regulation and may contribute to the onset of depression and other psychological disorders [82].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [82]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [142]
Experimental — accuracy not yet measuredIn the citing paper
“exenatide, administered at the dose approved for type 2 diabetes treatment, crosses the BBB in appreciable quantities and improves the motor and cognitive function of PD patients.”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [616]
In the citing paper
“This study provides in vivo evidence that “beta-cell rest” can at least temporarily allow insulin secretory capacity recovery, and in vitro studies examining the effect of diazoxide on diabetic human islets produced similar findings.177”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.004 · Cited by 32
RetractedHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Self-citationSystematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R. L., Patel, S., Rick, C., Gray, R. G., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R. A., Feigin, P. D., Jankovic, J. J., Lang, A. E., Langston, J. W., Melamed, E., Poewe, W. H., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 902
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 864
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M. R., Reske, S. N., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Rémy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 831
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645
Cited by
Sorted by citations
Items 301–400 of 887
Tackling dipeptidyl peptidase IV in neurological disorders
Castorina, A., Al‐Badri, G., Leggio, G. M., Musumeci, G., Marzagalli, R., & Drago, F. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.224365 · Cited by 34
“Moreover, a very recent clinical trial testing exenatide in PD patients has proven to be promising, with significant improvements in motor scores, which were sustained beyond the period of drug exposure (Athauda et al., 2017).”
BackgroundCan dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Cheng, Q., Cheng, J., Cordato, D. J., & Gao, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107559 · Cited by 34
Payne, T., Sassani, M., Buckley, E. E., Moll, S., Anton, A., Appleby, M., Maru, S., Taylor, R. N., McNeill, A., Hoggard, N., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038911 · Cited by 34
Self-citationArbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.4c09114 · Cited by 38
Sun, Y., Guo, C., Yuan, L., Li, W., Wang, Z., Yue, F., & Li, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00063 · Cited by 30
“Some anti-diabetic drugs have also been proven to be beneficial for PD patients (Athauda et al., 2017).”
BackgroundSöderbom, G., & Zeng, B. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.023 · Cited by 32
Current Concepts and Controversies in the Management of REM Sleep Behavior Disorder
Matar, E., McCarter, S. J., Louis, E. K. S., & Lewis, S. J. G. (2021) · Neurotherapeutics · doi:10.1007/s13311-020-00983-7 · Cited by 34
Nutritional Ketosis in Parkinson's Disease — a Review of Remaining Questions and Insights
Choi, A. H., Hallett, M., & Ehrlich, D. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01067-w · Cited by 35
“, insulin-sensitizing exenatide, an incretin, with positive primary outcome on motor score in phase 2 trial) [81].”
BackgroundDrug repurposing strategies of relevance for Parkinson’s disease
Fletcher, E. J. R., Kaminski, T. W., Williams, G. H., & Duty, S. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.841 · Cited by 31
Boosting mitochondrial health to counteract neurodegeneration
Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 36
“, 2022) Exenatide, possibly via enhancing mitochondrial biogenesis, improved Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) motor scores in PD patients (Athauda et al., 2017) Ambroxol increased mitochondrial biogenesis and mitochondrial content and reduce alphasynuclein levels in vitro and in vivo (…”
BackgroundParkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Dopamine Pharmacodynamics: New Insights
Lauretani, F., Giallauria, F., Testa, C., Zinni, C., Lorenzi, B., Zucchini, I., Salvi, M., Napoli, R., & Maggio, M. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105293 · Cited by 36
Ros-Madrid, I., Cano-Mármol, R. P., Ferrer-Gomez, M., & Ramos-Molina, B. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0148 · Cited by 31
Green, H., Tsitsi, P., Markaki, I., Aarsland, D., & Svenningsson, P. (2019) · CNS Drugs · doi:10.1007/s40263-018-0601-x · Cited by 31
Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?
Waragai, M., Ho, G. J., Takamatsu, Y., Wada, R., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00108 · Cited by 32
Current Management and Emerging Therapies in Multiple System Atrophy
Burns, M. R., & McFarland, N. R. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00890-x · Cited by 34
Jang, S. E., Qiu, L., Chan, L. L., Tan, E., & Zeng, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.558532 · Cited by 34
Potentially repurposable drugs for schizophrenia identified from its interactome
Karunakaran, K. B., Chaparala, S., & Ganapathiraju, M. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-48307-w · Cited by 29
REM sleep behaviour disorder: an early window for prevention in neurodegeneration?
Weil, R. S., & Morris, H. R. (2019) · Brain · doi:10.1093/brain/awz014 · Cited by 31
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 32
Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut
Morrow, N. M., Morissette, A., & Mulvihill, E. E. (2024) · Peptides · doi:10.1016/j.peptides.2024.171200 · Cited by 32
“GLP-1RAs are also being explored preclinically and clinically as a treatment for metabolic-associated fatty liver disease [29], Parkinson ’ s and Alzheimer ’ s disease [30 – 32].”
Therapies to Slow, Stop, or Reverse Parkinson’s Disease
Foltynie, T., & Langston, J. W. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181481 · Cited by 30
“There has been a lot of publicity surrounding the potential of Glucagon-like peptide 1 (GLP-1) receptor agonists in PD [24, 25].”
BackgroundSelf-citationMehan, S., Bhalla, S., Siddiqui, E. M., Sharma, N., Shandilya, A., & Khan, A. (2022) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s247153 · Cited by 29
Guttuso, T. J., Andrzejewski, K. L., Lichter, D. G., & Andersen, J. K. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.016 · Cited by 29
Li, Y., Glotfelty, E. J., Namdar, I., Tweedie, D., Olson, L., Hoffer, B. J., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113113 · Cited by 29
Self-citationKreiner, F. F., von Scholten, B. J., Kurtzhals, P., & Gough, S. C. L. (2023) · Aging Cell · doi:10.1111/acel.13818 · Cited by 27
McIntyre, R. S., Rasgon, N., Goldberg, J. F., Wong, S., Le, G. H., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Stahl, S. M. (2025) · CNS Spectrums · doi:10.1017/s1092852925000124 · Cited by 32
Research on developing drugs for Parkinson's disease
Zhang, C., Han, Q.-W., Chen, N., & Yuan, Y. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.017 · Cited by 28
Labandeira, C. M., Bau, A. F., Ron, D. A., Muñoz, A., Losada, G. A., Koukoulis, A., Romero-López, J., & Rodriguez-Perez, A. I. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100914 · Cited by 28
Zhang, P., Mao, C., Sun, A., Yang, Y., Hou, Y., Fu, Z., Tousi, B., Leverenz, J. B., Pieper, A. A., Luo, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70639 · Cited by 27
“24,25 For PD, exenatide has shown a beneficial effect on motor ability in two phase 2 trials and is currently being assessed in a phase 3 trial, 26–28 lixisenatide also showed beneficial effect on motor ability in a phase 2 trial, 29 and liraglutide and semaglu-tide are currently being evaluated in…”
The promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 31
“Two early exenatide studies suggested motor and cognitive benefits that persisted beyond drug washout (154–156), accompanied by CSF detection of the drug and enhanced brain insulin signaling (157).”
InfluentialSelf-citationSu, Y., Zhang, Z., Li, H., Ma, J., Sun, L., Shao, S., Zhang, Z., & Hölscher, C. (2020) · Drug Research · doi:10.1055/a-1266-3263 · Cited by 27
“A phase II clinical trial in PD patients showed that a GLP-1 receptor agonist is effective in treating PD patients [24].”
BackgroundParkinson’s Disease Detection Using Ensemble Architecture from MR Images
Mostafa, T. A., & Cheng, I. (2020) · IEEE International Conference on Bioinformatics and Bioengineering (BIBE) · doi:10.1109/bibe50027.2020.00167 · Cited by 27
“Some new forms of treatment like Exenatide [6]”
BackgroundDrug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 30
“After 48 weeks of treatment, the exenatide-treated group exhibited a statistically significant reduction in the progression of their MDS-UPDRS III motor features compared to the placebo treated control group (Athauda et al., 2017).”
BackgroundSemaglutide Protects against 6‐OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
Liu, D.-X., Zhao, C.-S., Wei, X., Ma, Y.-P., & Wu, J.-K. (2022) · Parkinson s Disease · doi:10.1155/2022/6813017 · Cited by 27
“Semaglutide has similar safety to the previous GLP-1 analogs for the treatment of diabetes, without new adverse reactions [12].”
Hernández‐Parra, H., Cortés, H., Ávalos‐Fuentes, J. A., Prado-Audelo, M. L. D., Florán, B., Leyva‐Gómez, G., Sharifi‐Rad, J., & Cho, W. C. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01612-5 · Cited by 30
Recent research progress on metabolic syndrome and risk of Parkinson’s disease
Li, L., Liu, S., Zhuang, J.-L., Li, M.-M., Huang, Z., Chen, Y., Chen, X., Chen, C., Lin, S., & Ye, L. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0093 · Cited by 30
Piątkowska‐Chmiel, I., Herbet, M., Gawrońska‐Grzywacz, M., Pawłowski, K., Ostrowska-Leśko, M., & Dudka, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06341-7 · Cited by 34
Yu, S., Wang, Y., Shen, H., Bae, E.-K., Li, Y., Sambamurti, K., Tones, M. A., Zaleska, M. M., Hoffer, B. J., & Greig, N. H. (2024) · GeroScience · doi:10.1007/s11357-024-01116-0 · Cited by 28
“This hypothesis is supported by preclinical studies of incretin mimetics across cellular and animal models of dopaminergic cell loss and PD [35, 61, 62] and, additionally, by the successful efficacy of the GLP-1 receptor agonist Exenatide in patients with moderate PD [26–30].”
BackgroundSelf-citationGLP‐1 receptor agonists for Parkinson's disease: An updated meta-analysis
de Albuquerque, M. B., Nunes, L. E. D. B., Maldonado, J. V. D. O., Ferreira, D. G. M., Margato, M. M., Rabelo, L. V., Valênça, M. M., & Cordeiro, L. H. O. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107220 · Cited by 26
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 35
Smedinga, M., Darweesh, S. K. L., Bloem, B. R., Post, B., & Richard, E. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10162-5 · Cited by 28
A New Approach to the Development of Disease‐Modifying Therapies for PD ; Fighting Another Pandemic
Kieburtz, K. D., Katz, R. G., McGarry, A. J., & Olanow, C. W. (2020) · Movement Disorders · doi:10.1002/mds.28310 · Cited by 26
“Multiple study designs have been used to assess potential disease-modifying therapies for PD (see Table 1).(16-33) The first major clinical trial seeking to slow PD progression was the DATATOP study.”
MethodDeischinger, C., Dervić, E., Kaleta, M., Klimek, P., & Kautzky‐Willer, A. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202486 · Cited by 26
Zhou, S., Tian, Y., Song, X., Xiong, J., & Cheng, G. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac245 · Cited by 26
Function and therapeutic value of astrocytes in diabetic cognitive impairment
Meng, F., Fu, J., Zhang, L., Guo, M., Zhuang, P., Yin, Q., & Zhang, Y. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105591 · Cited by 26
Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
Csóti, I., Herbst, H., Urban, P. P., Woitalla, D., & Wüllner, U. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02026-8 · Cited by 26
GLP-1, Parkinson’s Disease, and Neuroprotection
Standaert, D. G. (2024) · New England Journal of Medicine · doi:10.1056/nejme2401743 · Cited by 26
Sun, H., Hao, Y., Liu, H., & Gao, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1525623 · Cited by 32
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 25
Zhang, Z., Li, H., Su, Y., Ma, J., Yuan, Y., Yu, Z., Shi, M., Shao, S., Zhang, Z., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.814430 · Cited by 26
MED13 and Glycolysis Are Conserved Modifiers of α-Synuclein-Associated Neurodegeneration
Ren, M., Yang, Y., Heng, K. H. Y., Ng, L. Y., Chong, C. Y.-Y., Ng, Y. T., Gorur-Shandilya, S., Lee, R. M. Q., Lim, K. L., Zhang, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111852 · Cited by 24
Old wines in new bottles: Repurposing opportunities for Parkinson's disease
Kakkar, A. K., Singh, H., & Medhi, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.023 · Cited by 25
Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?
de la Monte, S. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240069 · Cited by 28
“…therapeutic roles in neurodegeneration due to MCI, T2DM, AD, and PD, as evidenced by experimental and clinical data demonstrating neuroprotection and preventive actions against cognitive decline [60] [70, 147] [148] and dementia progression in AD and PD, independent of T2DM [70, 147] [149, 150].”
Zhai, Y., Lu, K., Yuan, Y., Zhang, Z., Xue, L., Zhao, F., Xu, X., & Wang, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329439 · Cited by 24
“41,42 Notably, AD is characterized by brain insulin resistance, a phenomenon that has led to its collo-quial designation as “ type 3 diabetes ” .”
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 30
Body-wide multi-omic counteraction of aging with GLP-1R agonism
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Chan, R. C. H., Chan, D. T.-M., Wang, Z., Zheng, X., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.014 · Cited by 31
Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro
Takaku, S., Tsukamoto, M., Niimi, N., Yako, H., & Sango, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062971 · Cited by 24
“In contrast, Ex-4 has been approved as a safe and effective anti-diabetic agent [2] and its repurposing for patients with Parkinson’s diseases is an ongoing project [5,46].”
BackgroundBergkvist, L., Johnson, M., Mercado, G., Steiner, J. A., Meyerdirk, L. K., Schulz, E., Madaj, Z., Ma, J., Becker, K., Li, Y., et al. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113693 · Cited by 24
Self-citationDysmetabolism and Neurodegeneration: Trick or Treat?
Capucho, A. M., Chegão, A., Martins, F. O., Miranda, H. V., & Conde, S. V. (2022) · Nutrients · doi:10.3390/nu14071425 · Cited by 26
Lietzau, G., Magni, G., Kehr, J., Yoshitake, T., Candeias, E., Duarte, A. I., Pettersson, H., Skogsberg, J., Abbracchio, M. P., Klein, T., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.004 · Cited by 26
Diabetes, BMI, and Parkinson's
Foltynie, T., & Athauda, D. S. (2020) · Movement Disorders · doi:10.1002/mds.27941 · Cited by 24
Self-citationKopp, K. O., Li, Y., Glotfelty, E. J., Tweedie, D., & Greig, N. H. (2024) · Biomolecules · doi:10.3390/biom14070872 · Cited by 24
Self-citationInsulin Resistance Is a Modifying Factor for Parkinson's Disease
Žagare, A., Hemedan, A. A., Serra-Almeida, C., Frangenberg, D., Gomez‐Giro, G., Antony, P. M. A., Halder, R., Krüger, R., Glaab, E., Ostaszewski, M., et al. (2024) · Movement Disorders · doi:10.1002/mds.30039 · Cited by 25
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink‐Jensen, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70004 · Cited by 26
Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy
Guo, X., Song, D., Wu, M., Zhang, J., Li, J., & Yuan, L. (2025) · MedComm · doi:10.1002/mco2.70540 · Cited by 31
“In a case– control study, exenatide treatment over a 12‑month period led to a 15% improvement in UPDRS scores in early‑stage PD patients, alongside a reduction in CSF neuroinflammatory markers [256].”
Myeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 25
Combined drug triads for synergic neuroprotection in retinal degeneration
Maneu, V., Lax, P., de Diego, A. M. G., Cuenca, N., & de Diego, A. M. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112911 · Cited by 23
Lo, C., Arora, S., Lawton, M., Barber, T. R., Quinnell, T. G., Dennis, G. J., Ben‐Shlomo, Y., & Hu, M. T.-M. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327880 · Cited by 21
Lin, Y., Hsu, C., Liu, J., Chang, K., & Huang, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-49870-z · Cited by 23
“Two clinical trials have demonstrated that Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, improves both cognitive symptoms and motor deficits of PD patients 11,12 .”
BackgroundOverview of the Gut–Brain Axis: From Gut to Brain and Back Again
Post, Z., Manfready, R. A., & Keshavarzian, A. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771464 · Cited by 25
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 52
“While preclinical data are promising, clinical evidence in PD patients is still limited, but some studies have suggested potential benefits [137].”
Li, Y., Vaughan, K. L., Tweedie, D., Jung, Y. J., Kim, H. K., Choi, H.-I., Kim, D. S., Mattison, J. A., & Greig, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53356-2 · Cited by 22
Self-citationExendin-4 for Parkinson's disease
Esparza-Salazar, F. D. J., Lezama-Toledo, A. R., Rivera-Monroy, G., & Borlongan, C. V. (2021) · Brain Circulation · doi:10.4103/bc.bc_21_21 · Cited by 22
“The first clinical trial entailed a double‐blind randomized study of self‐administered exenatide or placebo in 62 participants over 48 weeks of treatment then followed by a 12‐week washout interval.[16] The second clinical trial involved a single‐blinded randomized study over a 12‐month period of self‐administered exe…”
BackgroundMethodGut-Brain Communication in Parkinson’s Disease: Enteroendocrine Regulation by GLP-1
Manfready, R. A., Forsyth, C. B., Voigt, R. M., Hall, D. A., Goetz, C. G., & Keshavarzian, A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01196-5 · Cited by 24
Wang, V., Tseng, K.-Y., Kuo, T., Huang, E. Y., Lan, K.-L., Chen, Z., Ma, K., Greig, N. H., Jung, Y. J., Choi, H.-I., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01025-6 · Cited by 23
“Our prior studies have demonstrated that this drug dose (0.6 mg/kg of Exenatide within 30 mg/kg PT320) maintains steady-state levels [24–26].”
BackgroundInfluentialSelf-citationType 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Kopp, K. O., Glotfelty, E. J., Li, Y., Lahiri, D. K., & Greig, N. H. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102343 · Cited by 22
Self-citationThe Linked Clinical Trials initiative ( LCT ) for Parkinson's disease
Brundin, P., & Wyse, R. K. H. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14175 · Cited by 22
Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease
Sancandi, M., Schul, E. V., Economides, G., Constanti, A., & Mercer, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00479 · Cited by 22
Prospects for Disease Slowing in Parkinson Disease
Menozzi, E., & Schapira, A. H. V. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022124-033653 · Cited by 23
Hölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 26
“The trial lasted for 48 weeks, and patients were tested at the beginning and the end and retested 12 weeks after treatment had stopped to test whether the drug effect was still visible [184].”
Tian, M.-J., Wang, R., Hölscher, C., Mi, R., Yuan, Z., Li, D., & Xue, G. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.05.008 · Cited by 21
Targeting Mitochondria as a Therapeutic Approach for Parkinson’s Disease
Abrishamdar, M., Jalali, M. S., & Farbood, Y. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01265-w · Cited by 22
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 26
Onset and mortality of Parkinson’s disease in relation to type II diabetes
Pezzoli, G., Cereda, E., Amami, P., Colosimo, S., Barichella, M., Sacilotto, G., Zecchinelli, A., Zini, M., Ferri, V., Bolliri, C., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11496-y · Cited by 21
“A randomized controlled trial of exenatide—a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat T2D—found that the drug had positive effects on practically all off-medication motor features, which persisted even beyond the period of drug exposure [21].”
BackgroundExendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease
Verma, A., Chaudhary, S., Solanki, K., Goyal, A., & Yadav, H. N. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14426 · Cited by 21
“However, exenatide treatment did not result in significant improvements in MDRS (Mattis dementia rating scale–2) scores or quality of life when compared to the placebo group (Athauda et al., 2017).”
BackgroundVanzolini, K. L., Ainsworth, S., Bruyneel, B., Herzig, V., Seraus, M. G. L., Somsen, G. W., Casewell, N. R., Cass, Q. B., & Kool, J. (2018) · Toxicon · doi:10.1016/j.toxicon.2018.06.080 · Cited by 21
Movassat, J., Delangre, E., Liu, J., Gu, Y., & Janel, N. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00649 · Cited by 21
“Indeed, exenatide, a glucagon-like peptide-1 (GLP-1) agonist used for the treatment of T2D led to improvements in motor assessments in patients with Parkinson’s disease (85).”
BackgroundThe Role of Intermittent Fasting in Parkinson's Disease
Neth, B. J., Bauer, B. A., Benarroch, E. E., & Savica, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.682184 · Cited by 24
Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20
Stockmann, O., Ye, L., Greten, S., Chemodanow, D., Wegner, F., & Klietz, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02882-7 · Cited by 20
“Similar trials with GLP-1 receptor agonists exenatide (Athauda et al. 2017) and NLY01, a brain-penetrant, pegylated, longer-lasting version of exenatide (McGarry et al. 2024) also showed positive effects on motor symptoms of PD patients.”
Jovanović, P., Wang, Y., Vit, J., Novinbakht, E., Morones, N., Hogg, E. J., Tagliati, M., & Riera, C. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263074 · Cited by 22
“The anti-diabetic drug exanitide, which activates GLP-1 receptors was shown to have a beneficial impact on motor symptoms in a cohort of 60 moderate stage PD patients [58].”
BackgroundSatapathy, T., & Kumar, D. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100499 · Cited by 20
Cancer enzyme affects Parkinson's disease
Brundin, P., & Wyse, R. K. H. (2018) · Science · doi:10.1126/science.aav3986 · Cited by 20
Neural-Derived Extracellular Vesicles in Clinical Trials
Dubal, D. B., & Pleasure, S. J. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4325 · Cited by 20
Clinical Trial Highlights – GLP-1 agonists
McFarthing, K., Larson, D., & Simuni, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-200002 · Cited by 20
Bain, E., & Bain, S. C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 21
Mishra, A., & Krishnamurthy, S. (2019) · Neurotoxicity Research · doi:10.1007/s12640-018-9983-2 · Cited by 20
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 25
“…double-blind, placebo-controlled trial in people with moderate PD observed improvements in motor scores, measured using the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale, following 48 weeks of exenatide treatment (EXENATIDE-PD NCT01971242) 164 .”
Metadata
- Authors
- Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., Li, Y., Aviles-Olmos, I., Warner, T. T., Limousin, P., Lees, A. J., Greig, N. H., Tebbs, S., & Foltynie, T.
- Affiliations
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- National Institute on Aging (US)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 390
- Issue
- 10103
- Pages
- 1664-1675
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5831666
- OpenAlex
- W2744843428
- Cited by
- 889
- References
- 38
- Citations by year
- 2026: 114 · 2025: 136 · 2024: 114 · 2023: 73 · 2022: 85 · 2021: 93 · 2020: 98 · 2019: 77 · 2018: 77 · 2017: 20
- FWCI
- 51.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Research (University of Surrey) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- National Institutes of Health (Z99 AG999999)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, exenatide, GLP-1 receptor agonists, neuroprotection, motor symptoms, off-medication state, dopaminergic therapy, neurodegeneration, adverse events, injection site reactions, gastrointestinal symptoms, drug repurposing, disease-modifying therapy
- MeSH terms
- Exenatide, Adult, Aged, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neurologic Examination, Parkinson Disease, Peptides, Venoms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
